Commonwealth Equity Services, LLC Fibrogen Inc Transaction History

Commonwealth Equity Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 11, 2021	SELL	$18.57 - $35.68 $121,392 - $233,240	-6,537 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$37.09 - $48.97 $148 - $195	4 Added 0.06%	6,537 $242,000
Q3 2020 Nov 05, 2020	SELL	$40.47 - $45.5 $6,353 - $7,143	-157 Reduced 2.35%	6,533 $268,000
Q2 2020 Aug 12, 2020	BUY	$32.57 - $42.83 $1,856 - $2,441	57 Added 0.86%	6,690 $271,000
Q1 2020 May 11, 2020	BUY	$23.3 - $45.96 $2,330 - $4,596	100 Added 1.53%	6,633 $230,000
Q2 2019 Jul 19, 2019	BUY	$35.13 - $55.53 $229,504 - $362,777	6,533 New	6,533 $295,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $37.5M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.